Regeneron Pharmaceuticals' Return on Capital Employed fell 200.0% to 0.1% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.1%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 0.1% for FY2025, which is 200.0% down from last year.
Per Regeneron Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.1% for Q4 2025, which was down 200.0% from 0.11% recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Return on Capital Employed registered a high of 0.43% during Q4 2021, and its lowest value of 0.1% during Q4 2025.
Over the past 5 years, Regeneron Pharmaceuticals' median Return on Capital Employed value was 0.16% (recorded in 2023), while the average stood at 0.21%.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Return on Capital Employed soared by 1800bps in 2021, and later crashed by -2500bps in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.43% in 2021, then crashed by -57bps to 0.19% in 2022, then fell by -26bps to 0.14% in 2023, then fell by -14bps to 0.12% in 2024, then decreased by -16bps to 0.1% in 2025.
Its last three reported values are 0.1% in Q4 2025, 0.11% for Q3 2025, and 0.11% during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value